| Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. HH Bailey, RT Mulcahy, KD Tutsch, RZ Arzoomanian, D Alberti, ... Journal of clinical oncology 12 (1), 194-205, 1994 | 224 | 1994 |
| Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly JH Schiller, BE Storer, PL Witt, D Alberti, MB Tombes, R Arzoomanian, ... Cancer research 51 (6), 1651-1658, 1991 | 174 | 1991 |
| The effects of hydrogen peroxide rinses on the normal oral mucosa MB Tombes, B Gallucci Nursing research 42 (6), 332-337, 1993 | 99 | 1993 |
| Phase Ib trial of bryostatin 1 in patients with refractory malignancies. S Grant, J Roberts, E Poplin, MB Tombes, B Kyle, D Welch, M Carr, ... Clinical cancer research: an official journal of the American Association …, 1998 | 70 | 1998 |
| Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms B Holkova, EB Perkins, V Ramakrishnan, MB Tombes, E Shrader, ... Clinical cancer research 17 (10), 3388-3397, 2011 | 62 | 2011 |
| Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion SC Remick, JL Grem, PH Fischer, KD Tutsch, DB Alberti, LM Nieting, ... Cancer research 50 (9), 2667-2672, 1990 | 56 | 1990 |
| Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation JD Roberts, EA Poplin, MB Tombes, B Kyle, DV Spicer, S Grant, T Synold, ... Cancer chemotherapy and pharmacology 45, 103-110, 2000 | 50 | 2000 |
| A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2 B Holkova, JG Supko, MM Ames, JM Reid, GI Shapiro, EB Perkins, ... Clinical Cancer Research 19 (7), 1873-1883, 2013 | 47 | 2013 |
| Clinical and biologic effects of combination therapy with gamma‐interferon and tumor necrosis factor JH Schiller, PL Witt, B Storer, D Alberti, MB Tombes, R Arzoomanian, ... Cancer 69 (2), 562-571, 1992 | 45 | 1992 |
| A phase II trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma B Holkova, A Zingone, M Kmieciak, P Bose, AZ Badros, PM Voorhees, ... Clinical Cancer Research 22 (5), 1067-1075, 2016 | 44 | 2016 |
| Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-d-Arabinofuranosylcytosine in Patients with Refractory Acute … LH Cragg, M Andreeff, E Feldman, J Roberts, A Murgo, M Winning, ... Clinical cancer research 8 (7), 2123-2133, 2002 | 41 | 2002 |
| A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma V Yazbeck, D Shafer, EB Perkins, D Coppola, L Sokol, KL Richards, ... Clinical Lymphoma Myeloma and Leukemia 18 (9), 569-575. e1, 2018 | 40 | 2018 |
| Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) KD Tutsch, RZ Arzoomanian, D Alberti, MB Tombes, C Feierabend, ... Investigational new drugs 17, 63-72, 1999 | 37 | 1999 |
| Phase I trial of bortezomib (PS-341; NSC 681239) and “nonhybrid”(bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory … B Holkova, M Kmieciak, EB Perkins, P Bose, RC Baz, GD Roodman, ... Clinical cancer research 20 (22), 5652-5662, 2014 | 27 | 2014 |
| Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas B Holkova, M Kmieciak, P Bose, VY Yazbeck, PM Barr, MB Tombes, ... Leukemia & lymphoma 57 (3), 635-643, 2016 | 26 | 2016 |
| Phase I study of sorafenib and vorinostat in advanced hepatocellular carcinoma SW Gordon, WP McGuire III, DA Shafer, RK Sterling, HM Lee, ... American Journal of Clinical Oncology 42 (8), 649-654, 2019 | 24 | 2019 |
| A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or … B Holkova, V Yazbeck, M Kmieciak, P Bose, S Ma, A Kimball, MB Tombes, ... Leukemia & lymphoma 58 (6), 1349-1357, 2017 | 20 | 2017 |
| Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial HD Bear, J Roberts, D Cornell, MB Tombes, B Kyle Cancer Immunology, Immunotherapy 50, 269-274, 2001 | 20 | 2001 |
| Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks JD Roberts, S Shibata, DV Spicer, HL McLeod, MB Tombes, B Kyle, ... Cancer chemotherapy and pharmacology 45, 423-427, 2000 | 20 | 2000 |
| Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma D Shafer, MB Tombes, E Shrader, A Ryan, D Bandyopadhyay, P Dent, ... Neuro-Oncology Advances 2 (1), vdz052, 2020 | 18 | 2020 |
